• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 19th December 2014

Spotlight on OHE: EQ-5D-5L, Next Generation Sequencing, and MCDA

For information on OHE at ISPOR Europe please see earlier posts: OHE at ISPOR Europe 1 and OHE at ISPOR Europe 2.   Does the choice of health state comparator or ordering of dimensions matter when valuing EQ-5D-5L? OHE’s Koonal…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email
For information on OHE at ISPOR Europe please see earlier posts: OHE at ISPOR Europe 1 and OHE at ISPOR Europe 2.
 
Does the choice of health state comparator or ordering of dimensions matter when valuing EQ-5D-5L?
OHE’s Koonal Shah delivered a presentation at the 1st Meeting of the International Academy of Health Preference Research in Amsterdam on 8th November 2014. Koonal presented findings from a methodological study to assess the impact on the valuation of EQ-5D-5L health states of: 
(i) different dimension orderings; 
(ii) different time trade-off comparator health states. 
 
This work was funded by the EuroQol Group as part of its EQ-VT research methodology programme
 

Ispor choice health-state-comparator-matter_eq_5_d_5l-kks_nov2014 from Office of Health Economics
OHE and its collaborators at the University of Sheffield are involved in a number of research studies examining the valuation of EQ-5D-5L health states. At a recent OHE seminar, Professors Nancy Devlin and Ben van Hout jointly presented findings from their study ‘An EQ-5D-5L value set for England’. 
 
For additional information please contact Koonal Shah at OHE.
 
Next Generation Sequencing: An HTA perspective on the implications for drug reimbursement
 
Speaking in Amsterdam on 13th November 2014 Adrian Towse delivered a presentation at the 3rd Annual Health Economics & Personalised Medicine Symposium on the topic of next generation sequencing (NGS). The talk explained the advantages of NGS, and explored the areas in which it may add most value. Adrian acknowledged the challenges of NGS, noting that demonstrating clinical utility is likely to be difficult. He concluded that NGS could enable drugs to be better targeted, yet may lead to an increase in costs. Health technology assessment (HTA) in this area will be crucial.
 

Next_generation_sequencing_AKT_Nov14 from Office of Health Economics
 
For more information please contact Adrian Towse at OHE.

MCDA for valuing orphan medicines. A pilot study

OHE’s Martina Garau delivered a presentation at the 12th Conference of the Polish Pharmacoeconomics Society (part of the ISPOR Poland chapter) in Warsaw on 4th December 2014. Martina’s presentation included an introduction on the use of multiple criteria decision analysis (MCDA) in health care decision making and a discussion of the method and finding of a practical application of MCDA to assess the value of orphan medicines.

MCDA for orphan_medicines_mg_dec2014 from Office of Health Economics

The results of the pilot study were published in Value in Health (http://www.valueinhealthjournal.com/article/S1098-3015%2813%2904356-8/abstract) 

An earlier version of the article was published as an OHE research paper and can accessed at
https://www.ohe.org/publications/multi-criteria-decision-analysis-value-orphan-medicines

For additional information please contact Martina Garau at OHE

  • EQ-5D and PROMs
  • Measuring and Valuing Outcomes
  • Pricing and Reimbursement

Related News

  • News
  • November 2021

Opportunity Cost in Health Care: a Favourite Research Topic for OHE

Read more
  • News
  • September 2020

Cornerstones of ‘Fair’ Drug Coverage

Read more
  • News
  • September 2020

Establishing a Reasonable Price for an Orphan Drug

Read more
  • News
  • June 2020

The 2020 OHE Annual Lecture Explores the Question: How Should the World Pay for a COVID-19 Vaccine?

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!